Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.
Saved in:
| Title: | Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy. |
|---|---|
| Authors: | Hearps AC; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC, Australia., Vootukuru N; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; Department of Gastroenterology, Eastern Health and Monash University, Melbourne, VIC, Australia., Ebrahimnezhaddarzi S; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia., Harney BL; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Boo I; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia., Nguyen L; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia., Pavlyshyn D; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia., Dietze PM; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; National Drug Research Institute, Curtin University, Melbourne, VIC, Australia., Drummer HE; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.; Department of Microbiology, Monash University, Melbourne, VIC, Australia., Thompson AJ; Department of Gastroenterology, St Vincent's Hospital and the University of Melbourne, Melbourne, VIC, Australia., Jaworowski A; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC, Australia., Hellard ME; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.; The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia., Sacks-Davis R; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia., Doyle JS; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC, Australia. |
| Source: | Frontiers in immunology [Front Immunol] 2024 Feb 14; Vol. 15, pp. 1352440. Date of Electronic Publication: 2024 Feb 14 (Print Publication: 2024). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
